Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Trisomy 8 in pediatric acute myeloid leukemia : A NOPHO-AML study

Laursen, Anne Cathrine Lund ; Sandahl, Julie Damgaard ; Kjeldsen, Eigil ; Abrahamsson, Jonas ; Asdahl, Peter ; Ha, Shau Yin ; Heldrup, Jesper LU ; Jahnukainen, Kirsi ; Jónsson, Ólafur G. and Lausen, Birgitte , et al. (2016) In Genes Chromosomes and Cancer 55(9). p.719-726
Abstract

Trisomy 8 (+8) is a common cytogenetic aberration in acute myeloid leukemia (AML); however, the impact of +8 in pediatric AML is largely unknown. We retrospectively investigated 609 patients from the NOPHO-AML database to determine the clinical and cytogenetic characteristics of +8 in pediatric AML and to investigate its prognostic impact. Complete cytogenetic data were available in 596 patients (98%) aged 0–18 years, diagnosed from 1993 to 2012, and treated according to the NOPHO-AML 1993 and 2004 protocols in the Nordic countries and Hong Kong. We identified 86 patients (14%) with +8. Trisomy 8 was combined with other cytogenetic aberrations in 68 patients (11%) (+8 other) and in 18 patients (3%), it was the sole abnormality (+8... (More)

Trisomy 8 (+8) is a common cytogenetic aberration in acute myeloid leukemia (AML); however, the impact of +8 in pediatric AML is largely unknown. We retrospectively investigated 609 patients from the NOPHO-AML database to determine the clinical and cytogenetic characteristics of +8 in pediatric AML and to investigate its prognostic impact. Complete cytogenetic data were available in 596 patients (98%) aged 0–18 years, diagnosed from 1993 to 2012, and treated according to the NOPHO-AML 1993 and 2004 protocols in the Nordic countries and Hong Kong. We identified 86 patients (14%) with +8. Trisomy 8 was combined with other cytogenetic aberrations in 68 patients (11%) (+8 other) and in 18 patients (3%), it was the sole abnormality (+8 alone). Trisomy 8 was associated with FAB M5 (36%) but otherwise clinically comparable with non-trisomy 8 patients. Trisomy 8 was favorable in patients of young age and with t(9;11). Trisomy 8 alone was associated with older age (median age 10.1 years), FAB M2 (33%), and FLT3-ITD mutations (58%). The 5-year event-free survival for patients with +8 alone was 50% and 5-year overall survival was 75%. In conclusion, +8 is one of the most common cytogenetic aberrations in pediatric AML. Trisomy 8 positive AML is a heterogeneous group and the majority of cases have additional cytogenetic aberrations. Patients with +8 alone differed from patients with +8 other and were associated with older age, FAB M2, and FLT3-ITD aberrations. There were no differences in survival despite the more frequent occurrence of FLT3-ITD in +8 alone.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; and (Less)
publishing date
type
Contribution to journal
publication status
published
subject
in
Genes Chromosomes and Cancer
volume
55
issue
9
pages
8 pages
publisher
John Wiley & Sons Inc.
external identifiers
  • pmid:27153159
  • wos:000379952300005
  • scopus:84978100435
ISSN
1045-2257
DOI
10.1002/gcc.22373
language
English
LU publication?
no
id
784ff0d7-2646-4fe6-8244-88d10da72f03
date added to LUP
2016-11-29 15:05:06
date last changed
2024-09-08 02:02:20
@article{784ff0d7-2646-4fe6-8244-88d10da72f03,
  abstract     = {{<p>Trisomy 8 (+8) is a common cytogenetic aberration in acute myeloid leukemia (AML); however, the impact of +8 in pediatric AML is largely unknown. We retrospectively investigated 609 patients from the NOPHO-AML database to determine the clinical and cytogenetic characteristics of +8 in pediatric AML and to investigate its prognostic impact. Complete cytogenetic data were available in 596 patients (98%) aged 0–18 years, diagnosed from 1993 to 2012, and treated according to the NOPHO-AML 1993 and 2004 protocols in the Nordic countries and Hong Kong. We identified 86 patients (14%) with +8. Trisomy 8 was combined with other cytogenetic aberrations in 68 patients (11%) (+8 other) and in 18 patients (3%), it was the sole abnormality (+8 alone). Trisomy 8 was associated with FAB M5 (36%) but otherwise clinically comparable with non-trisomy 8 patients. Trisomy 8 was favorable in patients of young age and with t(9;11). Trisomy 8 alone was associated with older age (median age 10.1 years), FAB M2 (33%), and FLT3-ITD mutations (58%). The 5-year event-free survival for patients with +8 alone was 50% and 5-year overall survival was 75%. In conclusion, +8 is one of the most common cytogenetic aberrations in pediatric AML. Trisomy 8 positive AML is a heterogeneous group and the majority of cases have additional cytogenetic aberrations. Patients with +8 alone differed from patients with +8 other and were associated with older age, FAB M2, and FLT3-ITD aberrations. There were no differences in survival despite the more frequent occurrence of FLT3-ITD in +8 alone.</p>}},
  author       = {{Laursen, Anne Cathrine Lund and Sandahl, Julie Damgaard and Kjeldsen, Eigil and Abrahamsson, Jonas and Asdahl, Peter and Ha, Shau Yin and Heldrup, Jesper and Jahnukainen, Kirsi and Jónsson, Ólafur G. and Lausen, Birgitte and Palle, Josefine and Zeller, Bernward and Forestier, Erik and Hasle, Henrik}},
  issn         = {{1045-2257}},
  language     = {{eng}},
  month        = {{09}},
  number       = {{9}},
  pages        = {{719--726}},
  publisher    = {{John Wiley & Sons Inc.}},
  series       = {{Genes Chromosomes and Cancer}},
  title        = {{Trisomy 8 in pediatric acute myeloid leukemia : A NOPHO-AML study}},
  url          = {{http://dx.doi.org/10.1002/gcc.22373}},
  doi          = {{10.1002/gcc.22373}},
  volume       = {{55}},
  year         = {{2016}},
}